The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Vetlugina T.P.

Lobacheva O.A.

Mental Health Research Institute, Tomsk, Russia

Semke A.V.

Nauchno-issledovatel'skiĭ institut psikhicheskogo zdorov'ia Sibirskogo otdeleniia Rossiĭskoĭ akademii meditsinskikh nauk, Tomsk

Nikitina V.B.

Mental Health Research Institute», Tomsk, Russia

Bokhan N.A.

Nauchno-issledovatel'skiĭ institut psikhicheskogo zdorov'ia Tomskogo nauchnogo tsentra Sibirskogo otdeleniia RAMN

An effect of quetiapine on the immune system of patients with schizophrenia

Authors:

Vetlugina T.P., Lobacheva O.A., Semke A.V., Nikitina V.B., Bokhan N.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(7): 55‑58

DOI: 10.17116/jnevro20161167155-58

Read: 2422 times

Contact the author
Table of contents

AN EFFECT OF QUETIAPINE ON THE IMMUNE SYSTEM OF PATIENTS WITH SCHIZOPHRENIA
AN EFFECT OF QUETIAPINE ON THE IMMUNE SYSTEM OF PATIENTS WITH SCHIZOPHRENIA

To cite this article:

Vetlugina TP, Lobacheva OA, Semke AV, Nikitina VB, Bokhan NA. An effect of quetiapine on the immune system of patients with schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(7):55‑58. (In Russ.)
https://doi.org/10.17116/jnevro20161167155-58

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Modern concepts of sleep disturbances asso­ciated with mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):7-12
Asso­ciation of cortisol levels with psychopathological features of depression and therapeutic response in female patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):45-54
Factors supporting chro­nic inflammation in mental illness. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):7-15
Age transformation of leading clinical diagnoses in adolescents and young people with non-suicidal self-harm. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):48-56
Constitutional and morphological bases of suicidal beha­vior in patients with schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):52-56
Search for risk factors for slowed intra-atrial conduction in patients with schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):111-116
Search for neurophysiological markers of schi­zophrenia spectrum diso­rders: ocular microtremor and contrast sensitivity. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):228-236
Transcranial electrostimulation as part of combination therapy for mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(1):37-44
Resu­lts of the use of immune checkpoint inhi­bitors in the treatment of small cell lung cancer in real-life clinical practice: resu­lts of a single-center obse­rvational study. P.A. Herzen Journal of Onco­logy. 2025;(4):46-53
The rela­tionship between the state of the microbiota and oral hygiene, their impact on human health (literature review). Stomatology. 2026;(1):85-93
Abstract:

Objective. To study an effect of the atypical antipsychotic quetiapine on the immune system of patients with schizophrenia with account for treatment efficacy. Material and methods. Quetiapine was administered to 27 patients diagnosed with residual schizophrenia (F20.5) for 6 weeks in dose 200-400 mg/day; dynamic of clinical symptoms was evaluated with PANSS и CGI scales before administration of quetiapine and by week 6 of the treatment. Along with clinical assessments, immune indices were determined. Results. At the end of week 6 of treatment, statistically significant changes of PANSS psychopathological symptoms were noted. According to CGI scale, patients were divided into group 1 with high treatment efficacy (n=17) and group 2 with the low efficacy (n=10). Significant between-group differences before treatment were as follows: the decreased number of lymphocytes of CD3+- CD16+-phenotypes, increased number of HLADR+-lymphocytes and IgA level in group 2. The quetiapine therapy led to the positive dynamic of phagocytosis indices, CD16+-lymphocytes, decrease in the level of IgA. Conclusion. Possible predictors of treatment efficacy were found including the number of mature T (CD3+) lymphocytes, CD16+ natural killers, HLADR+ lymphocytes and IgA concentrations.

Keywords:

quetiapine
immunity
schizophrenia

Authors:

Vetlugina T.P.

Lobacheva O.A.

Mental Health Research Institute, Tomsk, Russia

Semke A.V.

Nauchno-issledovatel'skiĭ institut psikhicheskogo zdorov'ia Sibirskogo otdeleniia Rossiĭskoĭ akademii meditsinskikh nauk, Tomsk

Nikitina V.B.

Mental Health Research Institute», Tomsk, Russia

Bokhan N.A.

Nauchno-issledovatel'skiĭ institut psikhicheskogo zdorov'ia Tomskogo nauchnogo tsentra Sibirskogo otdeleniia RAMN

Close metadata

References:

  1. Leucht S, Pitschel-Walz G, Abraham D., Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research. 1999;35(1):51-68. doi: 10.1016/s0920-9964(98)00105-4
  2. Mosolov SN, Aleksandrovskij JuA, Vovin R.Ja, Kalinin VV, Avedisova AS, Ivanov MV, Mazo GJe, Sulimov GJu, Chahava VO, Borodin VI, Eremin AV. Novyj atipichnyj antipsihotik serokvel': rezul'taty rossijskih klinicheskih ispytanij. Psihiatrija i psihofarmakoterapija. 2003;2:3-7. (In Russ.).
  3. Jeong H, Lee M. Long-acting Injectable Antipsychotics in First-episode Schizophrenia. Clin Psychopharmacol Neurosci. 2013;11(1):1-6. doi: 10.9758/cpn.2013.11.1.1
  4. Nemeroff C, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. Journal Clinical Psychiatry. 2002;15(suppl 13):5-11.
  5. Smulevich AB. Spektr klinicheskih jeffektov kvetiapina (serokvelja) v uslovijah krupnogo psihiatricheskogo stacionara. Psihiatrija i psihofarmakoterapija. 2003;2:7-8. (In Russ.).
  6. Larmo I, de Nayer A, Windhager E, Lindenbauer B, Rittmannsberger H, Platz T, Jones A, Altman C. Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. Human Psychopharmacology: Clinical and Experimental. 2005;20(8):573-581. doi: 10.1002/hup.723
  7. Chue P, Malla A, Bouchard R, Lessard S, Ganesan S, Stip E, Johnson S, Chen E, Ahn Y, Kim Y, Robinson G, Schweikert C, Gendron A, Eriksson H. The long-term clinical benefit and effectiveness of switching to once-daily quetiapine extended release in patients with schizophrenia. Current Medical Research and Opinion. 2013;29(3):227-239. doi: 10.1185/03007995.2012.762903
  8. Hashimoto N, Toyomaki A, Honda M, Miyano S, Nitta N, Sawayama H, Sugawara Y, Uemura K, Tsukamoto N, Koyama T, Kusumi I. Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response-a prospective open-label study. Ann Gen Psychiatry. 2015;14(1):1. doi: 10.1186/s12991-014-0039-6
  9. Buchanan R, Kreyenbuhl J, Kelly D, Noel J, Boggs D, Fischer B, Himelhoch S, Fang B, Peterson E, Aquino P, Keller W. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. Schizophrenia Bulletin. 2010;36(1):71-93. doi: 10.1093/schbul/sbp116
  10. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel R, Geddes J, Kissling W, Stapf M, Lässig B, Salanti G, Davis J. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. doi: 10.1016/S0140-6736(13)60733-3
  11. Hutton P, Taylor P, Mulligan L, Tully S, Moncrieff J. Quetiapine immediate release v. placebo for schizophrenia: systematic review, meta-analysis and reappraisal. The British Journal of Psychiatry. 2015;206(5):360-370. doi: 10.1192/bjp.bp.114.154377
  12. Müller N. Immunology of schizophrenia. Neuroimmunomodulation. 2014;21(2-3):109-116. doi: 10.1159/000356538
  13. Haitov RM, Pinegin BV. Ocenka immunnogo statusa cheloveka v norme i pri patologii. Immunologija. 2001; 4:4-6. (In Russ.).
  14. Hrdlicka M, Dudova I. Atypical antipsychotics in the treatment of early-onset schizophrenia. Neuropsychiatr Dis Treat. 2015;11:907-913. doi: 10.2147/NDT.S82185
  15. Zhang X, Zhou D, Cao L, Zhang P, Wu G, Shen Y. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. Journal Clinical Psychiatry. 2004;65(7):940-947. doi: 10.4088/jcp.v65n0710
  16. Kljushnik TP, Zozulja SA, Androsova LV, Sarmanova ZV, Otman IN, Dupin AM, Abramova LI, Stoljarov SA, Shipilova ES, Borisova OA. Immunologicheskij monitoring jendogennyh pristupoobraznyh psihozov. Zhurnal nevrologii i psihiatrii im. C.C. Korsakova. 2014;114(2):37-41. (In Russ.).
  17. Vetlugina T, Lobacheva O, Sergeeva S, Nikitina V, Nevidimova T, Semke A. Adjunctive use of interferon γ inducer for treatment of patients with schizophrenia. Acta Neuropsychiatrica. 2015;16:1-8. doi: 10.1017/neu.2015.60
  18. Lobacheva OA. Sravnitel'naja ocenka immunomodulirujushhih jeffektov atipichnyh nejroleptikov. Sibirskij vestnik psihiatrii i narkologii. 2011;1:100-102. (In Russ.).
  19. Meltzer H, Elkis H, Vanover K, Weiner D, van Kammen D, Peters P, Hacksell U. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophrenia Research. 2012;141(2-3):144-152. doi: 10.1016/j.schres.2012.07.029
  20. Idova G, Davydova S, Cheido M, Zhukova E, Devoino L. Significance of initial emotional state for neuroimmunomodulation in conditions of activation and blockade of 5-HT1A receptors. Neuroscience and Behavioral Physiology. 2006;36(7):703-707. doi: 10.1007/s11055-006-0076-y
  21. Idova G, Alperina E, Cheido M. Сontribution of brain dopamine, serotonin and opioid receptors in the mechanisms of neuroimmunomodulation: evidence from pharmacological analysis. International Immunopharmacology. 2012;12(4):618-625. doi:10.1016/j.intimp.2012.02.010
  22. Müller N, Schwarz MJ. Immune System and Schizophrenia. Current Immunology Reviews. 2010;6(3):213-220. doi: 10.2174/157339510791823673
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.